Adds Cell Therapy Regulatory Consultant and Cryopreservation Expert
BOTHELL, Wash., Sept. 5 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced the expansion of its Scientific Advisory Board (SAB) with the addition of two leading experts in cell therapy quality and regulatory assurance and in cryopreservation of stem cells derived from cord blood, dental pulp, and other sources.
The new members are:
-- Scott R. Burger, MD - Principal of Advanced Cell and Gene Therapy, a
consulting firm specializing in cell, gene, and tissue-based therapies.
Dr. Burger works with clients in industry and academic centers
worldwide, providing assistance in process development and validation,
GMP/GTP manufacturing, GMP facility design and operation, regulatory
affairs, technology evaluation, and strategic analysis. He received his
M.D. from the University of Pennsylvania School of Medicine and
completed postgraduate training in Laboratory Medicine and a clinical
fellowship in Transfusion Medicine and a postdoctoral research
fellowship at Washington University in St. Louis. He serves on the USP
Cell, Gene and Tissue Therapies Expert Committee, the advisory boards
of several cell therapy biotechnology companies, and has served as
editor of the International Society for Cellular Therapy Telegraft, and
on the ISCT Executive Committee. A frequently invited speaker at
industry and academic conferences, he is the author of more than 100
scientific publications and presentations, and recipient of numerous
honors and awards.
-- Erik J. Woods, Ph.D. - Co-Founder, CEO and Laboratory Director of The
Genesis Bank, a private cord blood bank, and also Director of Genome
Resources, an anonymous donor and client depositor sperm bank. Both
laboratories are FDA registered and CLIA compliant. Dr. Woods received
his Bachelor of Arts degree in Biology from Indiana University in
Bloomington. He then went on to study cryobiology and biomedical
engineering at the Hillenbrand Biomedical Engineering Center at Purdue
University in West Lafayette, Ind., where he earned a Doctor of
Philosophy Degree. Dr. Woods then completed a Post Doctoral Fellowship
at the Herman B Wells Center for Pediatric Research at the Indiana
University School of Medicine in Indianapolis, where he developed
enhanced methods for the cryopreservation and banking of umbilical cord
blood derived stem cells. In 1997 Dr. Woods co-founded General
BioTechnology LLC, the parent company of The Genesis Bank, to apply
these techniques to practical applications. He holds two patents, has
published numerous scientific articles, reviews and book chapters, and
is a member of many professional scientific societies, including the
American Association of Blood Banks, the International Society for
Cellular Therapy, and The Cell Transplant Society. Dr. Woods is also on
the Board of Governors for the International Society for Cryobiology.
In addition to his position with The Genesis Bank, Dr. Woods is an
Adjunct Assistant Professor in the Department of Microbiology and
Immunology at the Indiana University School of Medicine.
BioLife Chairman and CEO Mike Rice commented: "We're delighted that Scott and Erik have joined our board of scientific advisors. Their expertise and experience in the cell therapy and cord blood banking industries will greatly benefit our strategic planning process, research activities, and the creation of relevant product marketing messages to reinforce the benefits of our HypoThermosol(R) and CryoStor(TM) preservation media products in these key markets."
Drs Burger and Woods join current SAB members Shelly Heimfeld, Ph.D., Director of the Cellular Therapy Laboratory at the Fred Hutchinson Cancer Research Center; Dayong Gao, Ph.D., Professor of Mechanical and Biomedical Engineering at the University of Washington; Darin Weber, Ph.D., Senior Consultant, Cell and Gene Therapies at Biologics Consulting Group; Andrew Hinson, Vice President of Clinical and Regulatory Affairs at Symphony Medical; and Lizabeth Cardwell, Principal of Compliance Consulting.
About BioLife Solutions
BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function. For more information please visit http://www.biolifesolutions.com.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Media Relations: Investor Relations:
Len Hall Matt Clawson
Allen & Caron Inc. Allen & Caron Inc.
(949) 474-4300 (949) 474-4300
|SOURCE BioLife Solutions, Inc.|
Copyright©2007 PR Newswire.
All rights reserved